Tuesday, July 14, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

NBC opens Olympics with ‘worst hand imaginable’

Last year, NBC Sports executives called the Tokyo Olympics their most challenging undertaking ever.

Now that experience is starting to look like a cakewalk.

For this month’s Winter Games in Beijing, NBC confronts an even trickier mix of challenges, threatening to diminish one of the network’s signature products and one of the last major draws to broadcast television.

The list of headaches is long: an event nearly free of spectators, draining excitement from the arena and ski slopes; the threat of star athletes testing positive for Covid, potentially dashing their Olympic dreams; and the vast majority of its announcers, including Johnny Weir and Tara Lipinski, offering color commentary from a network compound in Stamford, Conn., instead of China.

The rising political tensions between the United States and China, including over China’s human rights abuses, add a troubling cloud to a typically feel-good spectacle.

Source: New York Times

https://www.nytimes.com/2022/02/03/business/media/olympics-nbc.html

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!